Skip to Main Content
scipher medicine
  • Company
  • Solutions
  • Resources
  • Contact Us
A network-based framework to discover treatment-response-predicting biomarkers for complex diseases

A network-based framework to discover treatment-response-predicting biomarkers for complex diseases

Jul 29, 2024

Uday Shankar Shanthamallu, Casey Kilpatrick, Alex Jones, Jonathan Rubin, Alif Saleh, Albert-László Barabási, Viatcheslav R. Akmaev, Susan Dina Ghiassian ABSTRACT Precision medicine’s potential to transform complex autoimmune-disease treatment is often challenged...
A network-based framework to discover treatment-response-predicting biomarkers for complex diseases

Identifying TNFI Therapy Response in UC Patients Using Baseline Whole Blood Gene Expression Data

May 23, 2024

Shanthamallu, Uday Shankar ; Jones, Alexander ; Panés, Julián ; Corraliza Márquez, Ana Maria ; Salas, Azucena ; Akmaev, Slava ; Ghiassian, Susan Dina Background Non-response to TNF inhibitor (TNFi) therapies remains a challenge in UC/IBD management. Identification of...
Decision Impact Analysis to Measure the Influence of Molecular Signature Response Classifier Testing on Treatment Selection in Rheumatoid Arthritis

Decision Impact Analysis to Measure the Influence of Molecular Signature Response Classifier Testing on Treatment Selection in Rheumatoid Arthritis

Nov 10, 2023

Jeffrey R Curtis 1, Vibeke Strand 2, Steven J Golombek 3, George A Karpouzas 4 5, Lixia Zhang 6, Angus Wong 6, Krishna Patel 6, Jennifer Dines 6, Viatcheslav R Akmaev 7 Introduction:  Clinical guidelines offer little guidance for treatment selection following...
Confronting Step Therapy in Rheumatoid Arthritis: A Rheumatology Practice’s Experience Using PrismRA to Bypass Ineffective TNF Inhibitor Therapies

Confronting Step Therapy in Rheumatoid Arthritis: A Rheumatology Practice’s Experience Using PrismRA to Bypass Ineffective TNF Inhibitor Therapies

Aug 30, 2023

John Boone, Gary Crump and Rosie Walters Introduction Step Therapy (ST), also known as “Step Edit” or “Fail First”, is a policy adopted by third-party payers to minimize costs of prescription drug use by requiring patients to trial a less expensive, first-line...
Decision Impact Analysis to Measure the Influence of Molecular Signature Response Classifier Testing on Treatment Selection in Rheumatoid Arthritis

Patient Perceptions of Rheumatoid Arthritis Blood Work: A Cross-sectional Survey in the ArthritisPower Registry

Jun 29, 2023

William Nowell1, Shilpa Venkatachalam2, Kelly Gavigan1, Michael George3, Johanna Withers4, Laura Stradford5, Esteban Rivera1 and Jeffrey Curtis6, 1Global Healthy Living Foundation, Upper Nyack, NY, 2Global Healthy Living Foundation, New York, NY, 3University of...
Patient-Reported Outcomes in Rheumatoid Arthritis Correlate with Clinical Disease Activity Index Response in the Study to Accelerate Information of Molecular Signatures (AIMS)

Patient-Reported Outcomes in Rheumatoid Arthritis Correlate with Clinical Disease Activity Index Response in the Study to Accelerate Information of Molecular Signatures (AIMS)

Nov 14, 2022

Vibeke Strand1, Emelly Rusli2, Lixia Zhang2, Christina Le-Short2, Alix Arnaud2, Johanna Withers3 and Sam Asgarian2, 1Stanford University School of Medicine, Stanford, CA, 2Scipher Medicine Corporation, Waltham, MA, 3Scipher Medicine Corportaion, Waltham, MA...
« Older Entries
Scipher Medicine Logo

Company

  • About Us
  • Team/Advisors
  • Careers

Solutions

  • Diagnostics
  • Data Lake
  • Therapeutics
  • Market Access

Resources

  • News/Events
  • Press
  • Publications
  • Media Kit
Contact Us

info@sciphermedicine.com

Privacy Policy / Patient Opt-out Information / Notice of Privacy Practices / Terms of Use / Cookies Acknowledgement / Notice of Nondiscrimination

© 2024 Scipher Medicine. All rights reserved. Privacy Policy